Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2

Abstract Among the therapies against the pandemic SARS-CoV-2 virus, monoclonal Antibodies (mAbs) targeting the Spike glycoprotein represent good candidates to interfere in the Spike/ACE2 interaction, preventing virus cell entry. Since anti-spike mAbs, used individually, might be unable to block the...

Full description

Bibliographic Details
Main Authors:	Margherita Passariello, Chiara Gentile, Veronica Ferrucci, Emanuele Sasso, Cinzia Vetrei, Giovanna Fusco, Maurizio Viscardi, Sergio Brandi, Pellegrino Cerino, Nicola Zambrano, Massimo Zollo, Claudia De Lorenzo
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-05-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-90348-7

Similar Items

Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis
by: Margherita Passariello, et al.
Published: (2021-08-01)

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
by: Margherita Passariello, et al.
Published: (2020-08-01)

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
by: Cinzia Vetrei, et al.
Published: (2021-06-01)

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
by: Masaud Shah, et al.
Published: (2020-01-01)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
by: Margherita Passariello, et al.
Published: (2019-09-01)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.
by: Marnie L Fusco, et al.
Published: (2015-06-01)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.
by: Marnie L Fusco, et al.
Published: (2015-10-01)

The Different Colors of mAbs in Solution
by: Alexandre Ambrogelly
Published: (2021-05-01)

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
by: Tal Noy-Porat, et al.
Published: (2020-08-01)

Protective effects elicited by cow milk fermented with L. Paracasei CBAL74 against SARS-CoV-2 infection in human enterocytes
by: Lorella Paparo, et al.
Published: (2021-12-01)

Multiepitope Proteins for the Differential Detection of IgG Antibodies against RBD of the Spike Protein and Non-RBD Regions of SARS-CoV-2
by: Larissa R. Gomes, et al.
Published: (2021-09-01)

Developments and Challenges for mAb-Based Therapeutics
by: Satoshi Ohtake, et al.
Published: (2013-08-01)

Biopurification of monoclonal antibody (mAb) through crystallisation
by: Chen, WQ, et al.
Published: (2021)

Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing
by: Margherita Passariello, et al.
Published: (2019-08-01)

Assessing social and economic impact of subcutaneous mAbs in oncology
by: Americo Cicchetti, et al.
Published: (2018-05-01)

Studies on CD40mAb-adjuvanted conjugate vaccines
by: Sultana, Tessabelle
Published: (2014)

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein
by: Qizhong Lu, et al.
Published: (2021-01-01)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
by: Josée Golay, et al.
Published: (2020-10-01)

Identification of Potential Binding Sites of Sialic Acids on the RBD Domain of SARS-CoV-2 Spike Protein
by: Bingqian Li, et al.
Published: (2021-07-01)

The polybasic insert, the RBD of the SARS-CoV-2 spike protein, and the feline coronavirus – evolved or yet to evolve
by: Anshul Budhraja, et al.
Published: (2021-03-01)

Modification of RBD palm kernel and RBD palm stearin oil with ZDDP additive addition
by: Farhanah, A. N., et al.
Published: (2015)

Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.
by: Vincent Boudousq, et al.
Published: (2013-01-01)

Endoplasmic reticulum retention motif fused to recombinant anti-cancer monoclonal antibody (mAb) CO17-1A affects mAb expression and plant stress response.
by: Ilchan Song, et al.
Published: (2018-01-01)

Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells
by: Margherita Passariello, et al.
Published: (2020-02-01)

Comparative efficacy and safety of chimeric and recombinant anti-TNF-α mAbs
by: V. N. Drozdov, et al.
Published: (2021-05-01)

mAb Production Modeling and Design Space Evaluation Including Glycosylation Process
by: Ou Yang, et al.
Published: (2021-02-01)

Strategies for adaptation of mAb-producing CHO cells to serum-free medium
by: Costa A, et al.
Published: (2011-11-01)

Glycosylation characterization of therapeutic mAbs by top- and middle-down mass spectrometry
by: Bao Quoc Tran, et al.
Published: (2016-03-01)

Controlling the Glycosylation Profile in mAbs Using Time-Dependent Media Supplementation
by: Devesh Radhakrishnan, et al.
Published: (2017-12-01)

Plant Recycling for Molecular Biofarming to Produce Recombinant Anti-cancer mAb
by: Deuk-Su Kim, et al.
Published: (2016-07-01)

Tanezumab: a selective humanized mAb for chronic lower back pain
by: Webb MP, et al.
Published: (2018-02-01)

Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity
by: Thomas Phelan, et al.
Published: (2021-07-01)

Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages
by: Umesh Kalathiya, et al.
Published: (2021-02-01)

Rabbit Monoclonal Antibody Specifically Recognizing a Linear Epitope in the RBD of SARS-CoV-2 Spike Protein
by: Junping Hong, et al.
Published: (2021-07-01)

The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum
by: Lu Lu, et al.
Published: (2021-09-01)

A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response
by: Duško Lainšček, et al.
Published: (2021-04-01)

Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1
by: Ge Yang, et al.
Published: (2021-06-01)

Implementation of QbD strategies in the inoculum expansion of a mAb production process
by: Ole Jacob Böhl, et al.
Published: (2021-03-01)

Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
by: Puey-Ling Chia, et al.
Published: (2020-10-01)

Accelerating Biologics Manufacturing by Modeling: Process Integration of Precipitation in mAb Downstream Processing
by: Lara Julia Lohmann, et al.
Published: (2020-01-01)